Drug
Xylometazoline
Xylometazoline is a pharmaceutical drug with 4 clinical trials. Historical success rate of 100.0%.
Total Trials
4
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 3 completed trials
Completion Rate
100%(3/3)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Phase Distribution
Ph not_applicable
2
50%
Ph phase_3
1
25%
Ph phase_4
1
25%
Phase Distribution
0
Early Stage
0
Mid Stage
2
Late Stage
Phase Distribution4 total trials
Phase 3Large-scale testing
1(25.0%)
Phase 4Post-market surveillance
1(25.0%)
N/ANon-phased studies
2(50.0%)
Highest Phase Reached
Phase 4Trial Status & Enrollment
Completion Rate
100.0%
3 of 3 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
0
trials recruiting
Total Trials
4
all time
Status Distribution
Completed(3)
Other(1)
Detailed Status
Completed3
unknown1
Development Timeline
Analytics
Development Status
Total Trials
4
Active
0
Success Rate
100.0%
Most Advanced
Phase 4
Trials by Phase
Phase 31 (25.0%)
Phase 41 (25.0%)
N/A2 (50.0%)
Trials by Status
completed375%
unknown125%
Recent Activity
0 active trials
Showing 4 of 4
completednot_applicable
Xylometazoline During Nasal Flexible Bronchoscopy
NCT03424889
unknownnot_applicable
The Role of the Nose in Snoring and Sleep Apnea
NCT03072173
completedphase_4
Nasal Decongestion and Obstructive Sleep Apnea
NCT00630474
completedphase_3
Decongestant Effect, Timing of Effect and Impact on Sleep and General Well-Being of Xylometazoline in Subjects With a Common Cold
NCT00452270
Clinical Trials (4)
Showing 4 of 4 trials
NCT03424889Not Applicable
Xylometazoline During Nasal Flexible Bronchoscopy
NCT03072173Not Applicable
The Role of the Nose in Snoring and Sleep Apnea
NCT00630474Phase 4
Nasal Decongestion and Obstructive Sleep Apnea
NCT00452270Phase 3
Decongestant Effect, Timing of Effect and Impact on Sleep and General Well-Being of Xylometazoline in Subjects With a Common Cold
All 4 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 4